Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 76
- Registration Number
- NCT02268136
Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT02266485
Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders
Phase 1
Completed
- Conditions
- Urination Disorders
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02266524
Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 97
- Registration Number
- NCT02266537
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02266472
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Flomax®, Norman II facilityDrug: Flomax®, Nishine facility
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02266511
Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02266498
Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT02266550
Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIIL 284 BS tablet CDrug: BIIL 284 BS boliOther: standard breakfast
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02265640
Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: BIIL 284 BS, low dose, adult patientsDrug: BIIL 284 BS, high dose, pediatric patientsDrug: BIIL 284 BS, medium dose, pediatric patientsDrug: BIIL 284 BS, high dose, adult patientsDrug: PlaceboDrug: BIIL 284 BS, low dose, pediatric patientsDrug: BIIL 284 BS, medium dose, adult patients
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 45
- Registration Number
- NCT02265679